CJC / IPA Blend
Growth Hormone Secretagogue - CJC-1295 + Ipamorelin co-formulated GH-research blend.
A co-formulated blend pairing a GHRH analog with a selective secretagogue, prepared for researchers studying the two mechanisms in combination.
This blend exists because GHRH analogs and ghrelin-receptor secretagogues act through complementary mechanisms, and researchers frequently study them together to look at combined GH release. Co-formulation keeps the ratio fixed across a study.
CJC / IPA Blend specifications
- Molecular formula
- Co-formulated blend
- Sequence
- CJC-1295 + Ipamorelin
- Residues
- CJC-1295 + Ipamorelin
- Presentation
- Lyophilized powder
- Documented purity
- 99.97% by HPLC
- Available sizes
- 10mg ($55)
- Archived COA lots
- 8
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Dual GH stimulation - Studied for combined GHRH and ghrelin-receptor activity on GH release.
Reported mechanisms in the literature
- Dual GH stimulation - Pairs a GHRH analog with a selective secretagogue, studied for combined GHRH- and ghrelin-receptor activity on GH release. (Combination research)
What CJC / IPA Blend is researched for
- Dual stimulation - Studied for combined GHRH-analog and ghrelin-receptor activity on GH release. (Combination research)
- Pulse amplitude - Investigated for combined effects on GH pulse amplitude in research models. (Preclinical literature)
CJC / IPA Blend certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| H2XMF1 | 27 Jul 2026 | 10mg | Accurate Test Labs | 99.93% | Confirmed (LC-MS/MS) | COA PDF |
| Auth2607200246 | 22 Jul 2026 | 10mg | Freedom Diagnostics | 99.88% | Confirmed (LC-MS/MS) | COA PDF |
| Auth2605110194 | 15 May 2026 | 10mg | Freedom Diagnostics | 99.96% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2605110194 | 11 May 2026 | 5mg | Freedom Diagnostics | 99.96% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2602180086 | 20 Feb 2026 | 5mg | Freedom Diagnostics | 99.97% | Confirmed (LC-MS/MS) | COA PDF |
| 1100001 | 20 Feb 2026 | 10mg | Freedom Diagnostics | 99.97% | Confirmed (LC-MS/MS) | COA PDF |
| IPCJ12092025-J | 11 Dec 2025 | 10mg | Freedom Diagnostics | 99.85% | Confirmed (LC-MS/MS) | COA PDF |
| IPCJ12092025-J | 10 Dec 2025 | 5mg | Freedom Diagnostics | 99.85% | Confirmed (LC-MS/MS) | COA PDF |
Published literature on CJC / IPA Blend
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
Research notes: CJC / IPA Blend
Background
This is a co-formulated preparation of CJC-1295, a GHRH-receptor analog, and ipamorelin, a ghrelin-receptor agonist. The pairing exists because the two release growth hormone through different receptors and are reported to act synergistically: GHRH and growth-hormone-releasing peptides together produce more release than either alone, and the determinants of that synergy have been studied in men (Veldhuis and Bowers, 2009; Arvat et al., 2001). Co-formulating them fixes the ratio across a study, which removes one source of variation when the interaction is the question.
What the Aspect certificates show
There are 8 certificate records for the 5mg and 10mg vials, from two laboratories (Accurate Test Labs and Freedom Diagnostics), dated 10 December 2025 to 27 July 2026. Reported HPLC purity runs from 99.85% to 99.97%. Identity is confirmed by LC-MS/MS, and the appearance is reported as white lyophilized powder. A blend is reported as a whole, and some reports list the two components' contents separately, so read the PDF for the component split of a given lot. Each full report is available as a PDF on this page and in the COA library.
How it differs from related compounds
The single-compound pages, CJC-1295 DAC, CJC-1295 and Ipamorelin, are the references for each arm. Choose the single compounds when one receptor is the variable and the blend when the combined response is.
Citations
Veldhuis JD, Bowers CY, Am J Physiol Endocrinol Metab 2009 (PMID 19240251). Arvat E et al., J Clin Endocrinol Metab 2001 (PMID 11238504).
Third-party publications are cited for context and are not Aspect Peptides claims. For laboratory research use only.
CJC / IPA Blend frequently asked questions
What is the CJC / IPA blend?
A co-formulation pairing CJC-1295 (a GHRH analog) with Ipamorelin (a selective secretagogue), for researchers studying the two GH mechanisms together.
Is it approved for human use?
No. Neither component is approved for human use; the blend is a research material only.
How is it documented?
The vial ships with a Certificate of Analysis for the combined lot.
Documented to 99.97% purity by HPLC · third-party COA every lot · from $55 · For laboratory research use only.
Related Growth Hormone compounds
- Tesamorelin - GHRH analog studied for growth-hormone-axis research.
- TESA / IPA Blend - Tesamorelin + Ipamorelin co-formulated GH-research blend.
- Ipamorelin - Selective GH secretagogue studied for receptor-selective GH release.
- CJC-1295 - GHRH analog studied for sustained GH signaling.
- CJC-1295 DAC - Long-acting GHRH analog with drug-affinity complex.
- Sermorelin - GHRH(1-29) fragment studied for GH-axis research.